Sky Century Investment (SKYI) Net Income towards Common Stockholders (2024 - 2026)
Sky Century Investment (SKYI) reported Net Income towards Common Stockholders of $5913.0 for Q1 2026, up 122.11% year-over-year from $2662.2 in Q1 2025, and up 120.96% quarter-over-quarter from -$28213.0 in Q4 2025.
Sky Century Investment (SKYI) Net Income towards Common Stockholders (2024 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has 3 years of Net Income towards Common Stockholders data on file, last reported at $5913.0 in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at $5913.0, up 122.11% year-over-year; the trailing twelve-month figure through Feb 2026 was -$71152.0 (up 26.75% YoY), and the FY2025 annual result was -$117225.0, down 60.76% from the prior year.
- Net Income towards Common Stockholders improved to $5913.0 in Q1 2026 per SKYI's latest filing, from -$28213.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $5913.0 in Q1 2026 and troughed at -$41628.0 in Q4 2024.
- A 3-year average of -$22687.8 and a median of -$26745.0 in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders slumped 145.07% in 2025, then jumped 122.11% in 2026.
- A 3-year view of Net Income towards Common Stockholders shows it stood at -$41628.0 in 2024, then jumped by 32.23% to -$28213.0 in 2025, then jumped by 120.96% to $5913.0 in 2026.
- Business Quant data shows SKYI's Net Income towards Common Stockholders at $5913.0 in Q1 2026, -$28213.0 in Q4 2025, and -$35805.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Sky Century Investment | - | - | 31,666.00 | 5,913.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 5,913.00 |
| Nov 30, 2025 | -28,213.00 |
| Aug 31, 2025 | -35,805.00 |
| May 31, 2025 | -13,047.00 |
| Feb 28, 2025 | -26,745.00 |
| Nov 30, 2024 | -41,628.00 |
| Aug 31, 2024 | -14,610.00 |
| May 31, 2024 | -14,149.00 |
| Feb 29, 2024 | -35,906.00 |